# Phase 1/2 syndrome trials recruiting: 61 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 61 trials in phase 1/2 for syndrome that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 syndrome trials: 61 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/syndrome

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 61
- Recruiting or not yet: 61
- Read on: November 19, 2026

## Trials

The 25 newest of 61, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07934186 | LM11A-31 Safety and Tolerability in Aging People Living With HIV and Neurocognitive Impairment | University of North Carolina, Chapel Hill | Phase 1/2 | Not yet recruiting | HIV-ASSOCIATED NEUROCOGNITIVE DISORDER (HAND) | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934186) |
| November 9, 2026 | NCT07925801 | Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol Secretion | The University of Texas Health Science Center at San Antonio | Phase 1/2 | Not yet recruiting | Type 2 Diabetes, Hypercortisolism | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925801) |
| November 4, 2026 | NCT07917390 | ALT-100 Monoclonal Antibody (mAb) in Bone-Predominant Metastatic Androgen Pathway Modulation Resistant (APMR) Prostate Cancer -- The... | University of Florida | Phase 1/2 | Not yet recruiting | Prostate Cancer Metastatic to Bone | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917390) |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| October 27, 2026 | NCT07897448 | A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) | Grand Theravac Life Sciences (Hangzhou) Co., Ltd. | Phase 1/2 | Not yet recruiting | Chronic Hepatitis B | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897448) |
| September 22, 2026 | NCT07832370 | A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD) | Regeneron Pharmaceuticals | Phase 1/2 | Not yet recruiting | Prion Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832370) |
| September 4, 2026 | NCT07804004 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease | CRISPR Therapeutics | Phase 1/2 | Not yet recruiting | Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804004) |
| July 31, 2026 | NCT07738107 | ATR 1072 in Participants With PRKAG2 Syndrome | Atrium Therapeutics | Phase 1/2 | Recruiting | Cardiac Glycogenosis, Cardiomyopathy, Hypertrophic, Wolff-Parkinson-White Syndrome | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738107) |
| July 7, 2026 | NCT07688096 | Regenerative Medicine for Joint Hypermobility and Instability | Manhattan Pain Medicine, PLLC | Phase 1/2 | Not yet recruiting | Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS), Joint Hypermobility, Joint Instability... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07688096) |
| July 2, 2026 | NCT07682402 | Taurine Supplementation in Adolescents With Post-COVID Condition | University of Alberta | Phase 1/2 | Not yet recruiting | Long COVID, Post COVID-19 Condition, PASC Post Acute Sequelae of COVID 19 | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07682402) |
| May 12, 2026 | NCT07579247 | Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS | Shanghai Public Health Clinical Center | Phase 1/2 | Not yet recruiting | HIV, AIDS, Immune Checkpoint Inhibitors, Refractory Opportunistic Infection | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07579247) |
| May 11, 2026 | NCT07577986 | A Safety and Efficacy Trial of Chidamide Combined With NKG2D CAR-NK Cell Therapy for Reducing the HIV Viral Reservoir | First Affiliated Hospital of Zhejiang University | Phase 1/2 | Not yet recruiting | HIV (Human Immunodeficiency Virus) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07577986) |
| April 17, 2026 | NCT07535710 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma | Shanghai Jiao Tong University School of Medicine | Phase 1/2 | Not yet recruiting | Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed, Sezary Syndrome, Cutaneous T Cell Lymphoma... | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07535710) |
| March 18, 2026 | NCT07481422 | Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndrome | University of Rijeka | Phase 1/2 | Recruiting | Irritable Bowel Syndrome (IBS) | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07481422) |
| February 27, 2026 | NCT07439848 | Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis | PT. Prodia Stem Cell Indonesia | Phase 1/2 | Recruiting | Acute Respiratory Distress Syndrome | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07439848) |
| February 17, 2026 | NCT07413978 | A Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Severe Acute Respiratory Distress Syndrome | Changchun Tuohua Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Acute Respiratory Distress Syndrome | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07413978) |
| February 10, 2026 | NCT07398508 | NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Menkes Disease | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07398508) |
| February 3, 2026 | NCT07384624 | Combining Latency Reversing Agents to Address the HIV Reservoir | Erasmus Medical Center | Phase 1/2 | Not yet recruiting | HIV (Human Immunodeficiency Virus), HIV -1 Infection | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07384624) |
| January 28, 2026 | NCT07374419 | Atamparib in Patients With Advanced Solid Tumors | Nerviano Medical Sciences (Shanghai) Ltd. | Phase 1/2 | Recruiting | NSCLC Adenocarcinoma, Solid Tumor | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07374419) |
| September 18, 2025 | NCT07181837 | A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome | MavriX Bio, LLC | Phase 1/2 | Recruiting | Angelman Syndrome | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07181837) |
| September 16, 2025 | NCT07175493 | A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia | Keymed Biosciences Co.Ltd | Phase 1/2 | Recruiting | Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia, Evans Syndrome | 158 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07175493) |
| August 7, 2025 | NCT07110662 | New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. | Hospices Civils de Lyon | Phase 1/2 | Not yet recruiting | Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR) | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07110662) |
| July 14, 2025 | NCT07062523 | Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT | Peking Union Medical College Hospital | Phase 1/2 | Recruiting | Sjogren's Syndrome | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07062523) |
| July 11, 2025 | NCT07061470 | A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | Phase 1/2 | Not yet recruiting | ADHD, Sleep Problems | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07061470) |
| June 10, 2025 | NCT07012304 | Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Chronic Graft Versus Host Disease | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07012304) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 5 |
| Peking University Third Hospital | 2 |
| PT. Prodia Stem Cell Indonesia | 1 |
| Cell Energy Life Sciences Group Co. LTD | 1 |
| CytoAgents, Inc. | 1 |
| Copenhagen University Hospital, Rigshospitalet | 1 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| Penn State University | 1 |
| University of Wisconsin, Madison | 1 |
| AC Immune SA | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
| Vanderbilt University Medical Center | 1 |
| University of Alberta | 1 |
| Sohag University | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
| Yale University | 1 |
| Nerviano Medical Sciences (Shanghai) Ltd. | 1 |
| University of Rijeka | 1 |
| Peking Union Medical College Hospital | 1 |
| Chang Gung Memorial Hospital | 1 |
| Medsyn Biopharma, LLC | 1 |
| Southeast University, China | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Hospital General Universitario Gregorio Marañon | 1 |
| CRISPR Therapeutics | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 28 |
| China | 11 |
| Spain | 5 |
| France | 4 |
| United Kingdom | 2 |
| Egypt | 2 |
| Canada | 2 |
| Indonesia | 1 |
| Denmark | 1 |
| Croatia | 1 |
| Switzerland | 1 |
| Taiwan | 1 |
| Austria | 1 |
| Australia | 1 |
| Ireland | 1 |
| Portugal | 1 |
| Russia | 1 |
| Netherlands | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Artificial turf companies in the United States](https://specstream.ai/data/businesses/artificial-turf-companies/united-states)
- [Lodges in the United States](https://specstream.ai/data/businesses/lodges/united-states)
- [B2B quarry companies in the United States](https://specstream.ai/data/businesses/b2b-quarry-companies/united-states)
- [Mills in the United States](https://specstream.ai/data/businesses/mills/united-states)
- [Book magazine distribution companies in the United States](https://specstream.ai/data/businesses/book-magazine-distribution-companies/united-states)
- [Otolaryngology practices in the United States](https://specstream.ai/data/businesses/otolaryngology-practices/united-states)
